Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer. Issue 2 (May 2015) - Howell, Matthew
Highlights Most immune related toxicities are low grade and easily manageable with treatment protocols. It is important to recognise and manage side effects promptly to improve safe delivery of immunotherapy. Frequent immune related adverse events and their management are discussed.